DNASE1 and systemic lupus erythematosus: Decreased degradation of NETs due to decreased activity of DNase1 in SLE patients may also lead to an increased tendency to thrombosis [133], therefore, targeted NETs therapy may be a new option for the clinical prevention and treatment of VTE in SLE patients.